Day One Biopharmaceuticals, Inc. (DAWN) News
Filter DAWN News Items
DAWN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
DAWN News Highlights
- DAWN's 30 day story count now stands at 2.
- Over the past 22 days, the trend for DAWN's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DEC are the most mentioned tickers in articles about DAWN.
Latest DAWN News From Around the Web
Below are the latest news stories about DAY ONE BIOPHARMACEUTICALS INC that investors may wish to consider to help them evaluate DAWN as an investment opportunity.
Day One to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceBRISBANE, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Dr. Jeremy Bender, chief executive officer, will present during the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8 at 10:30 a.m. Pacific Time / 1:30 p.m. Eastern Time. A live |
Milei to Send ‘Shock’ Package to Argentina’s Congress on Day One(Bloomberg) -- President-elect Javier Milei plans to call congress into an extraordinary session and send a large package of reforms to stabilize Argentina’s economy on Dec. 11, the day after his inauguration.Most Read from BloombergBillions Wiped Out as Stock-Safety Trade on Wall Street MisfiresRussia Downs Drones Over Moscow in Ukrainian Retaliatory StrikeTreasuries Extend Blockbuster Rally on Fed Wagers: Markets WrapMusk, Netanyahu Visit Massacre Site Amid Antisemitism FurorIsrael, Hamas Exte |
Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature MedicineData subsets to be shared today in plenary oral presentations at the 2023 Society for Neuro-Oncology Annual MeetingBRISBANE, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the publication of the registrational Phase 2 FIREFLY-1 trial results evaluating the |
Day One to Participate in the Piper Sandler 35th Annual Healthcare ConferenceBRISBANE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that management will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Tuesday, November 28 at 11:30 a.m. EST. A live audio webcast of the discussion will be av |
Day One Biopharmaceuticals Inc (DAWN) Reports Q3 2023 Financial Results and Corporate ProgressDAWN's Q3 2023 financial results reveal a net loss of $46.2 million and cash position of $405.5 million |
Day One Reports Third Quarter 2023 Financial Results and Corporate ProgressNDA for tovorafenib in relapsed or progressive pLGG accepted for FDA priority review PDUFA target action date of April 30, 2024 BRISBANE, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced its third quarter 2023 financial results and highlighted recent corpora |
12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge FundsIn this article we present the list of 12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds. Click to skip past our discussion of the biotech space and straight to the 5 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds. Alkermes plc (NASDAQ:ALKS), Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) and ImmunoGen, Inc. […] |
Apple’s Journal app has arrived – here’s what’s good and badHaving used Journal for a few days now, I feel confident saying that Day One is not staring down an existential threat -- at least not yet. Keep in mind we’re talking about Apple has a well-known history of Sherlocking new apps with feature updates (it was, after all, the company that gave rise to the term), but in its current form, the new journaling app still has a ways to go to catch up with Day One’s head start. After all, the Automattic-owned app has been kicking for more than a decade, at |
Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)Priority review granted with PDUFA target action date of April 30, 2024BRISBANE, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) for tovorafenib as a monotherapy in rel |
Tesla Stock Had a Horrible Day. Here’s What Comes Next.Tesla stock had another terrible day after earnings. Tesla stock (ticker: TSLA) tanked for the third consecutive time after the electric-vehicle maker reported quarterly numbers. Price cuts pushed operating profit margins below 8%, down almost 10 percentage points year over year. |